Asthma Drug Formoterol Shows Promise in Reversing Fatty Liver Disease
Researchers at the Medical University of South Carolina have discovered that formoterol, a drug commonly used to treat asthma and chronic obstructive pulmonary disease (COPD), may reverse liver damage associated with metabolic dysfunction-associated steatohepatitis (MASH). This condition is a severe form of fatty liver disease that can lead to liver failure and is a leading cause of liver transplants. The study, published in npj Metabolic Health and Disease, found that formoterol reversed liver damage in mice models. The drug appears to enhance mitochondrial function, which may be key to its effectiveness. The research team, led by Dr. Joshua Lipschutz, is now conducting clinical trials to evaluate the drug's potential benefits for humans, particularly those with diabetic kidney disease, as MASH often co-occurs with this condition. 
